• Mon news: Ventyx gets boost from Sanofi. PhRMA IRA legal challenge gets new life. AZ breast cancer drug disappoints. Teva’s once-monthly schizophrenia med. AZ gets FDA approval for first self-administered flu vaccine. See more on our front page

Axios: New Alzheimer's drug doesn't show net benefit, report finds


<







https://www-cnbc-com.cdn.ampproject...efits-of-leqembi-when-they-stop-the-drug.html


sorry it’s actually good news!!! Stop trying to scare people who realize this product is a breakthrough

Not quite.


https://seekingalpha.com/article/4592603-biogen-and-eisai-cassava-sciences-and-anavex-clinical-trial-results-in-need-of-revisions

Biogen And Eisai, Cassava Sciences, And Anavex: Clinical Trial Results In Need Of Revisions

Apr. 06, 2023 6:28 AM ET
Summary
  • Biogen and Eisa compared the effects of their drug Leqembi against the combined placebo decline rather than against the different rates of decline for APOE4 carriers and non-carriers.
  • This made Leqembi look more effective for non-carriers than it actually was while making APOE4 homozygotes look like they were actually getting worse on the drug compared to the placebo.